Ból pleców u młodego mężczyzny – częsta dolegliwość, wymagająca nierutynowego postępowania Case report
Main Article Content
Abstract
None
Article Details
How to Cite
Zubrzycka-Sienkiewicz, A. (2013). Ból pleców u młodego mężczyzny – częsta dolegliwość, wymagająca nierutynowego postępowania. Medycyna Faktow (J EBM), 6(1(18), 51-55. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2428
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Boonen A., van der Linden S.M.: The burden of ankylosing spondylitis. J. Rheumatol. Suppl. 2006; 78: 4-11.
2. Brophy S., Pavy S., Lewis P. et al.: Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J. Rheumatol. 2001; 28: 2667-2673.
3. Rudwaleit M., van der Heijde D., Khan M.A. et al.: How to diagnose axial spondyloarthritis early. Ann. Rheum. Dis. 2004; 63: 535-543.
4. Zochling J., van der Heijde D., Burgos-Vargas R. et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 2006; 65: 442-452.
5. Altan L., Bingol U., Karakoc Y. et al.: Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 2001; 30: 255-259.
6. Guidelines for the use of anti-TNF therapy in patients with ankylosing spondylitis. Spondylitis Association of America. Copyright 2006.
7. Dougados M., Behier J.M., Jolchine I. et al.: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001; 44: 180-185.
8. Huang J.Q., Sindhar S., Hunt R.H.: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metaanalysis. Lancet 2002; 359: 14-22.
9. Lanas A.: The appropriate use of proton-pump inhibitor co-therapy with nonsteroidal anti inflammatory drugs and cyclo-oxygenase 2 selective inhibitors. Aliment. Pharmacol. Ther. 2005; 21(Suppl. 1): 2-4.
10. Chan F.K., Cryer B., Goldstein J.L. et al.: A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J. Rheumatol. 2010; 37(1): 167-74.
11. Wanders A., van der Heijde D., Landewe R., Behier J.M. et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheuma. 2005; 52: 1756-65.
2. Brophy S., Pavy S., Lewis P. et al.: Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J. Rheumatol. 2001; 28: 2667-2673.
3. Rudwaleit M., van der Heijde D., Khan M.A. et al.: How to diagnose axial spondyloarthritis early. Ann. Rheum. Dis. 2004; 63: 535-543.
4. Zochling J., van der Heijde D., Burgos-Vargas R. et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 2006; 65: 442-452.
5. Altan L., Bingol U., Karakoc Y. et al.: Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 2001; 30: 255-259.
6. Guidelines for the use of anti-TNF therapy in patients with ankylosing spondylitis. Spondylitis Association of America. Copyright 2006.
7. Dougados M., Behier J.M., Jolchine I. et al.: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001; 44: 180-185.
8. Huang J.Q., Sindhar S., Hunt R.H.: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a metaanalysis. Lancet 2002; 359: 14-22.
9. Lanas A.: The appropriate use of proton-pump inhibitor co-therapy with nonsteroidal anti inflammatory drugs and cyclo-oxygenase 2 selective inhibitors. Aliment. Pharmacol. Ther. 2005; 21(Suppl. 1): 2-4.
10. Chan F.K., Cryer B., Goldstein J.L. et al.: A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J. Rheumatol. 2010; 37(1): 167-74.
11. Wanders A., van der Heijde D., Landewe R., Behier J.M. et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheuma. 2005; 52: 1756-65.